Lentiviral Fluorescent Genetic Barcoding for Multiplex Fate Tracking of Leukemic Cells

Tobias Maetzig,1,3 Jens Ruschmann,1 Lea Sanchez Milde,1 Courteney K. Lai,1 Niklas von Krosigk,1 and R. Keith Humphries1,2

Tracking the behavior of leukemic samples both in vitro and in vivo plays an increasingly large role in efforts to better understand the leukemogenic processes and the effects of potential new therapies. Such work can be accelerated and made more efficient by methodologies enabling the characterization of leukemia samples in multiplex assays. We recently developed three sets of lentiviral fluorescent genetic barcoding (FGB) vectors that create 26, 14, and 6 unique immunophenotyping-compatible color codes from GFP-, yellow fluorescent protein (YFP)-, and monomeric kusabira orange 2 (mKO2)-derived fluorescent proteins. These vectors allow for labeling and tracking of individual color-coded cell populations in mixed samples by real-time flow cytometry. Using the prototypical Hoxa9/Meis1 murine model of acute myeloid leukemia, we describe the application of the 6xFGB vector system for assessing leukemic cell characteristics in multiplex assays. By transplanting color-coded cell mixes, we investigated the competitive growth behavior of individual color-coded populations, determined leukemia-initiating cell frequencies, and assessed the dose-dependent potential of cells exposed to the histone deacetylase inhibitor Entinostat for bone marrow homing. Thus, FGB provides a useful tool for the multiplex characterization of leukemia samples in a wide variety of applications with a concomitant reduction in workload, processing times, and mouse utilization.

INTRODUCTION

Acute myeloid leukemia (AML) represents a severe acquired hematopoietic disease with low overall survival rates. Much effort is, therefore, being directed at better characterizing the AML mutational landscape, mutation-dependent transcriptional programs, and epigenetic signatures within the disease driving leukemic stem cell (LSC) population, which contains the functionally defined leukemia-initiating cells (LICs).1–9 In addition, major thrusts of current research are focused on establishing optimized in vitro cultivation systems for primary AML cells, as well as developing de novo AML models.10–16 With these advances, there is an increasing imperative for functional investigations. However, these often rely on labor- and cost-intensive in vitro and in vivo experiments. For example, pre-clinical in vitro drug efficacy testing requires subsequent in vivo evaluation assays to dissect the effects on blast cells and LSC properties with regards to engraftment, self-renewal, and survival, especially since these parameters may not be directly accessible by in vitro assays.17,18

Historically, hematopoietic research has extensively benefitted from the development of innovative marking and tracking techniques. While initial studies utilized congenic or autologous markers for distinguishing donor- and host-derived cells in transplantation assays,19–21 the advent of retroviral gene marking facilitated the stable genetic modification of target cells and fate tracking by fluorescent proteins and integration site analyses.22,23 The establishment of barcoded vector libraries further increased resolution and enabled the ability to track hundreds of cell clones with regards to size, differentiation potential, and dynamics of hematopoietic reconstitution in a single animal.24,25 The opportunity to achieve real-time resolution and to prospectively isolate cells of interest for consecutive studies, such as gene expression analyses or secondary transplantations, originated from the transition toward advanced fluorescence-based tracking approaches. Seminal studies utilized stochastic combinatorial expression methods of various fluorescent proteins in transgenic animals or in retrovirally transduced cells for creating defined hues compatible with fluorescent microscopy-assisted clonal cell tracking.26–28 Refinement of these techniques enabled the flow cytometric characterization of multiple uniquely labeled cell populations in multiplex assays by employing pre-defined fluorescent color codes as recently demonstrated by the in vivo tracking of transgenic murine HSC and lentivirally marked glioblastoma clones.29–32 In our work, we further expanded the scope of flow cytometric tracking applications by developing three lentiviral fluorescent genetic barcoding (FGB) vector systems.32 These FGB vectors encode for GFP, YFP, and mKO2 fluorescent proteins and variants (e.g., YFPe and mKO3), which facilitate the production of 26, 14, and 6 different color codes. In contrast to DNA barcoding, the 14x and 6xFGB systems require the initial labeling of separate cultures with single color codes expressed from individual vectors before mixing of samples and

Received 21 April 2017; accepted 28 May 2017;
http://dx.doi.org/10.1016/j.omtm.2017.05.007.
3Present address: Institute of Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany
Correspondence: Tobias Maetzig, Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada.
E-mail: tmaetzig@bccrc.ca
their flow cytometric deconvolution in multiplex studies. Additionally, the 6xFGB vector system links a defined DNA barcode (BC) to each color code (GFP-BCA, YFP-BC5, meKO3-BC6, YFPe-2A-GFP-BC8, GFP-2A-meKO3-BC28*, and YFP-2A-meKO3-BC31*). This approach thus enables immunophenotyping-compatible highly specific cell tracking by fluorescent signature, as well as by molecular techniques as demonstrated in cell lines and primary human and murine HSC in vitro and in vivo. Additionally, color-coded vectors equipped with microRNA (miRNA) co-expression cassettes revealed microRNA 126 (miR-126) induced in vitro expansion of a murine bone marrow (BM) cell line. These examples predict that multiplexing of color-coded cells will also have considerable potential for AML research. Here, the potential to directly compare properties of multiple samples within a single animal promises a reduction in host-dependent variability and thus offers the opportunity to reduce animal consumption in line with the replace, reduce, and refine (3R) guidelines without compromising on data quality. Potential applications of FGB include the investigation of LSC repopulation kinetics, LSC frequencies, and the competitive fitness of defined cell populations under normal conditions or in response to drug treatment. Additionally, applying FGB to longitudinal in vitro studies may lead to a reduction in processing times, culture-induced variability, and reagent expenses. To further explore the unique multiplexing capabilities of the 6xFGB system, we here describe its application in the Hoxa9/Meis1 (H9M) murine AML model.33 H9M leukemic cell lines support long-term in vitro cultivation and trigger aggressive leukemia with a latency of 40–60 days after transplantation.33,34 Through transplantation of color-coded H9M cell mixes, we monitored the dynamic competition between differently color-coded populations in recipient mice, established multiplex limiting dilution assays (MLDAs) and studied drug responses in short-term assays. Together, these experiments provide proof-of-principle that FGB enables the characterization of leukemia samples in multiplex assays and provides increased accuracy of data, while concomitantly allowing for a reduction in sample numbers. Therefore, FGB provides a powerful platform for accelerating leukemia research through multiplexing applications.

RESULTS

Lentiviral FGB Allows for Stable Color Coding of H9M AML Cells

To further evaluate the utility of the 6xFGB vector system for functional in vitro and in vivo multiplex assays (Figure 1A), we applied FGB to the prototypical H9M AML model by transducing four independently generated H9M lines with all six vectors in separate wells (Figure 1B). Four H9M replicate (Rep) lines, two derived from Pep3b (CD45.1Rep1 and CD45.1Rep2) and two derived from C57BL/6 (CD45.2Rep1 and CD45.2Rep2) mice, were employed to minimize potential cell line-associated artifacts and enable the separation of the donor- and host-derived cell content in congeneric transplantation experiments. After expansion, each of the 24 transduced samples was subjected to fluorescence-activated cell sorting (FACS) and sorting purities reached ≥95% in aliquots of single color-coded cells (Figures 1C and S1A). Also, flow cytometric analysis allowed for deconvolution of all six FGB input populations in mixed samples when first gating on meKO3 positive and negative cells before assessing the GFP and YFP expression in these gates (Figure 1D). Furthermore, single color-coded cells could be accurately detected by their BC in PCRs (Figure 1E). Longitudinal tracking of multiple aliquots per single color-coded population in isolation showed stable vector expression indicative of robust vector performance in H9M cells (Figures 1F and S1B). Additionally, the preparation of cell mixes containing all six FGB color-coded cell aliquots per parental H9M line in equal ratios offered the opportunity to track competitive growth behavior in culture. Therefore, assessment of the color code distribution on day 0 (d0) before splitting cells into four wells for subsequent cultivation allowed for investigating heterogeneous growth potential in aliquots from the same parental cell mixes. Flow cytometric analyses showed the stable maintenance of color codes at highly reproducible ratios in all replicates for the first 7 days of observation (Figures 1G and S1C). Interestingly, over time, some aliquots manifested the expansion of a single color-coded population, which was nevertheless stably maintained in other aliquots of the same parental cell mix. Statistical testing did not detect a significant growth advantage of any of the color codes, indicating that the assay reliably detects dynamic changes in the intrinsic competitiveness of color-coded cell populations rather than transgene-induced effects (Figure S1D).

In summary, single color-coded H9M populations allow for near-purity enrichment, show stable color code expression over time, and consequently facilitate the study of competitive growth behavior of differentially marked populations in mixed cultures.

Single Color-Coded H9M Populations Show Comparable Growth Properties In Vivo

To extend the utilization of our 6xFGB system to in vivo leukemia studies, we next sought to verify the stable maintenance of fluorescent labels without influencing cell properties; e.g., disease latency and surface marker composition. Therefore, each of the six CD45.1Rep2-derived color-coded populations was individually transplanted into groups of four mice (Figure 2A). At 3 and 5 weeks post-transplantation, as well as at the time of sacrifice, the peripheral blood (PB) showed color code expression in ~80% of donor-derived bulk CD45.1+ cells, as well as in myeloid cells (CD11b+Gr1+ and CD11b+ Gr1+) therein (Figures 2B; representative flow cytometry plots and gating strategies depicted in S2). Two (Gr1+ cKit+ and lineage marker negative cKit+, Lin- cKit+) of the three BM-derived LSC subpopulations defined by Gibbs et al. showed similar gene marking rates (Figures 2C; representative flow cytometry plots and gating strategies depicted in S3). In contrast, color code expression in the third (lymphoid [Lym]+cKit+) LSC subpopulation could not be analyzed due to the small size of this population in the majority of mice. Nevertheless, sorting procedures enabled the enrichment of LSC subpopulations from all color codes (Figure S4). Notably, the slightly higher degree of variation seen in groups BCA and BC8 was due to the continuous expansion of transgene negative cells in single mice, potentially originating from non-gene marked cells or from vector silencing. Similarly, in single animals of groups BC6 and BC28,
intermediate bright meKO3+ populations emerged, which required exclusion from analyses, and potentially developed due to variegated vector expression (Figures S5A–S5C).35 Regardless, mice from all six groups succumbed with a comparable latency of 45 days (Figure 2D). Therefore, the application of stringent gating criteria allowed for specific immunophenotypic characterization of differently color-coded samples, which displayed comparable lineage composition (Figures S5D and S5E) and transforming potential as a prerequisite for subsequent functional multiplexing studies.

Color-Coded H9M Cells Exhibit Heterogeneous Growth Behavior In Vivo
To assess the competitive behavior of H9M cells and to test the ability of FGB to resolve dynamic changes in H9M populations in vivo, we next transplanted cell mixes containing equal proportions of all six color-coded populations into lethally irradiated mice (Figure 3A). Longitudinal analyses of PB samples typically revealed the presence of all input color codes both 3 and 4 weeks after transplantation, although some mice displayed better preservation of the initial mixing ratios than others (representative mice shown in Figure 3B, left). However, between 4 and 5 weeks after transplantation, the mixing ratio of early detected color codes underwent rapid changes and led to the expansion of one or two dominant color codes. Due to this dynamic behavior, mice showed a steady decline from an average of four (at 3 weeks) to one (at 5 weeks) color-coded populations with contributions of ≥10% to PB lineages representative of the expansion of a single color code over time (Figure 3C). As expected, the bulk of the leukemic cell mass in the BM of moribund mice...
resembled the PB color code distribution from endpoint samples (Figure 3B, middle). However, when assessing color code distributions within the BM LSC subpopulations, some mice showed a good correlation between the overall PB and BM color code composition (e.g., mice 1 and 2), while others showed a stronger degree of variation (e.g., mice 3 and 4; Figures 3B, right, and S6). This observation suggests that separate cell populations with distinct differentiation preferences may form the three H9M LSC compartments.

To demonstrate the successful color coding of cells with disease propagating potential, unfractionated BM from two mice was transplanted into two paired secondary recipients, each (mice 3 and 4; Figures 3B and S7), and assessed for the engraftment potential of color-coded cells. Although the BM of these two donor mice contained two populations with >20% contributions to the Lin- cKit+ LSC compartment, thought to contain the highest frequency of LSC,34 the BM of paired secondary moribund mice was dominated by a single color code (Figure S7). In the case of mouse 4, this color code may have originated from a Lin- cKit+-derived minor population (Figure S7C). The observed color code expansion indicates that the color code distribution in primary recipients may not represent a steady state and that major and minor populations continue to compete in secondary recipients. Furthermore, this suggests the successful color coding of functionally defined LSC.

In summary, multiplex transplantation assays allowed for the tracking of dynamic fluctuations of color-coded H9M subpopulations over time. Similar to in vitro experiments, early time points revealed multiple color-coded populations, while later time points reported a progressive loss of color code complexity.

**FGB-Based Limiting Dilution Assays Show Differences in LIC Frequency**

Based on the relatively stable color code distributions early after initiation of in vitro and in vivo multiplexing experiments, we next sought to harness this behavior for performing LDAs with multiple cell concentrations in a single mouse. We hypothesized that a group of six mice, each transplanted with a unique cell mix containing 3 x 10^2, 3 x 10^3, 3 x 10^4, and 1 x 10^5 differently color-coded input cells, would allow determination of the LIC frequency based on monitoring 36 populations in parallel (Figure 4A). Similar to conventional LDAs, color code contributions <0.2% (equal to the smallest input population) of the total PB donor cell fraction would be scored “negative” in these MLDAs. However, due to the competitive nature of MLDAs, LIC frequencies can be assessed in the PB and BM over time rather than using the conventional dose-dependent survival as the only readout. Assessment of MLDA color code mixing ratios in aliquots of the injected cell mixes from our four independently generated H9M lines yielded an almost perfect correlation between the expected and observed mixing ratios, demonstrating the potential of the FGB platform to report quantitative differences in mixed cell populations (Figure 4B, top panel). Assessment of the PB color code distributions 2 weeks after transplantation and subsequent LIC frequency calculation reproduced the ~2-fold difference in self-renewing cell content already detected in vitro colony-forming cell assays between the CD45.1- and the CD45.2-derived H9M lines (Figures S8A and S8B), although these differences evened out at the 4 week time point (Figures 4B, middle panels, and 4C).38 However, in the PB of moribund mice, the highest LIC frequency was detected in sample CD45.1Rep2 (1 in 19,051), the second highest in CD45.2Rep2 (1 in 23,347), the third highest in CD45.1Rep1 (1 in
30,119), and the lowest in CD45.2Rep1 (1 in 51,052) (Figures 4B, bottom panel, and 4C), which inversely correlated with median survival times of 40.5 days (CD45.1Rep2), 45 days (CD45.2Rep2), 54 days (CD45.1Rep1), and 58.5 days (CD45.2Rep1), respectively (Figure 4D).

Importantly, and as expected, the PB and BM samples of moribund mice showed a similar distribution of color codes, which further underscores the utility of PB characterization for assessment of LIC frequencies in MLDAs (Figures S8C and S8D). Additionally, the detection of 62%, 19%, and 19% of dominant color codes in BM samples originating from the color codes with the highest (1 x 10^5), second highest (3 x 10^4), and third highest (1 x 10^4) input numbers, respectively, corroborates the quantitative nature of MLDAs (Figure S8E).

Taken together, this suggests that in contrast to conventional LDAs, MLDAs facilitate a quantitative and longitudinal assessment of LIC frequencies with unparalleled efficiency in a 6-fold reduced number of mice.

Figure 3. In Vivo Competition of Six Color-Coded H9M Populations Results in a Loss of Color Code Complexity over Time

(A) Experimental design. Purified color-coded cells were mixed in equal ratios and transplanted into lethally irradiated mice. The PB was sampled over time, and the PB and BM were analyzed in moribund mice. (B) Color code distribution within (left) donor-derived CD45+ PB cells over time, (middle) bulk BM cells, and (right) BM LSC subpopulations (subp.) of mice transplanted with 6xFGB transduced H9M (CD45.1 or CD45.2) cells. (C) Determination of color codes >10% contribution to the donor-derived PB cell fraction, from a total of 19 transplanted mice, 16, 18, 19, 12, and 18 were analyzed 3, 4, 5, and 6 weeks post-transplantation and at the time of sacrifice, respectively. The bar graphs from (C) represent mean values ± SD.

FGB-Based Multiplex Assays Reveal an Immediate Effect of In Vitro Entinostat Treatment on In Vivo Cell Properties

Given the quantitative nature of the FGB multiplex transplantation assays, we hypothesized that the FGB approach could also enable the characterization of in vivo LSC properties in response to in vitro drug treatment in a reduced number of mice. H9M cells were thus subjected to a series of functional in vitro and in vivo assays after challenge with the histone deacetylase (HDAC) inhibitor Entinostat (Figure 5A). Growth curves showed that all four H9M lines similarly tolerated up to 1 μM Entinostat exposure for 24 hr (Figure 5B). Likewise, mixing of color-coded Entinostat-exposed H9M cells in equal ratios revealed the disappearance of the 3 μM-treated sample within the first week of observation, whereas contributions of all other populations remained relatively stable for up to 28 days in culture (Figure 5C).

To further resolve potential in vitro effects of Entinostat on in vivo cell properties, we next investigated the Entinostat-dependent engraftment rate of transplanted H9M cells in short-term assays. These assays serve as surrogates for immediate drug effects on survival, differentiation, and migration capacity to the BM, which together reflect the cellular homing potential. For increasing the complexity
of traceable populations and for concomitantly reducing the number of required mice, drug treatment experiments of single color-coded H9M populations were repeated before mixing of CD45.1Rep1 with CD45.2Rep2 (group 1) and CD45.1Rep2 with CD45.2Rep1 (group 2) derived color-coded cells, respectively. The antibody-mediated detection of CD45.1- and CD45.2-derived input cells in these assays enables monitoring of 12 color-coded populations in a single culture well or CD45.1/C2 CD45.2 F1 animal (Figure 5A).

Figure 4. Multiplex Limiting Dilution Assays Detect Differences in LIC Frequency of Individual H9M Lines
(A) Mixing ratios of individual MLDAst with color-coded input cells of indicated doses. (B) Assessment of color code contributions to the total MLDA cell mix at the time of transplantation (d0) and within the donor-derived PB CD45.1+ or CD45.2+ cells 2 and 4 weeks after transplantation as well as at sacrifice (isac). The dotted line indicates 0.2% graft content as a cutoff for successful engraftment. The numbers at the top of each graph indicate the fraction of mice that showed successful engraftment. (C) Estimation of leukemia-initiating cell (LIC) frequency for each of the four H9M lines from (B). (D) Comparison of survival times of mice transplanted with MLDA H9M cell mixes. There were six mice that were transplanted per H9M line.

| MLDA mixing ratios | BCA | BCS | BCS | BC8 | BC28 | BC31 |
|--------------------|-----|-----|-----|-----|------|------|
| MLDA-1             | 1x10³| 3x10³| 1x10³| 1x10³| 1x10³| 1x10³|
| MLDA-2             | 1x10³| 3x10³| 1x10³| 1x10³| 1x10³| 1x10³|
| MLDA-3             | 3x10³| 1x10³| 3x10³| 1x10³| 1x10³| 1x10³|
| MLDA-4             | 1x10³| 3x10³| 1x10³| 1x10³| 1x10³| 1x10³|
| MLDA-5             | 3x10³| 1x10³| 3x10³| 1x10³| 1x10³| 1x10³|
| MLDA-6             | 1x10³| 3x10³| 1x10³| 1x10³| 1x10³| 1x10³|

Table 1. MLDA mixing ratios

| H9M line | CD45.1 | CD45.2 |
|----------|--------|--------|
| Rep1     | Rep2   | Rep1   | Rep2   |
| Estimate | 526    | 599    | 1137   | 1333   |
| Upper    | 251    | 289    | 566    | 661    |
| Lower    | 1102   | 1242   | 2288   | 2688   |
| Estimate | 916    | 1374   | 1385   | 1805   |
| Upper    | 455    | 687    | 693    | 904    |
| Lower    | 1846   | 2747   | 2770   | 3607   |
| Estimate | 30119  | 19051  | 51052  | 23347  |
| Upper    | 16658  | 9898   | 25451  | 11070  |
| Lower    | 54459  | 37425  | 102403 | 45240  |
Figure 5. Multiplex Drug Assay

(A) Experimental design for short-term Entinostat assays. CD45.1- and CD45.2-derived color-coded H9M cells were treated with Entinostat for 24 hr before assessment of cell growth by Vi-Cell counts. Treated cells from a CD45.1- and a CD45.2-derived H9M line were mixed in equal ratios to yield the “group 1” and “group 2” 12xFGF mixes for longitudinal in vitro tracking and injection into four CD45.1/C2 CD45.2 F1 mice per group. For comparison, non-treated 12xFGF cell mixes were prepared in parallel.

(B) AlamarBlue-dependent assessment of dose-dependent cell growth of four different H9M lines after 24 hr of Entinostat exposure (n = 3–4 per data point). (C) Each

Molecular Therapy: Methods & Clinical Development

60 Molecular Therapy: Methods & Clinical Development Vol. 6 September 2017
transplanted cell mixes, as well as in in vitro cultures, and in the BM extracted cells 24 hr later (Figures 5D, 5E, S9A, and S9B). In contrast, analysis of Entinostat-treated 12xFGB cell mixes 24 hr after injection revealed a dose-dependent decrease in homing potential at even lower concentrations than required for impairing in vitro cell growth (Figures 5F–5H, S9C, and S9D). Subsequent calculations of half maximal inhibitory concentration (IC50) values predicted a 50% decreased engraftment rate at Entinostat concentrations of 548.5 nM (CD45.1Rep1), 282.1 nM (CD45.1Rep2), 425.6 nM (CD45.2Rep1), and 599 nM (CD45.2Rep2) for our four H9M lines, respectively (Figure S1). Together, results from monitoring 96 non-treated and 96 Entinostat-treated populations in a total of 16 mice indicated a severe reduction in H9M cell homing potential shortly after in vitro Entinostat treatment. These observations underscore the importance of in vivo readouts for assessing in vitro drug responses and further illustrate the power of FGB to enable such readouts in an efficient manner with decreased mouse utilization.

**DISCUSSION**

Our study establishes the potential of lentiviral FGB for the multiplex characterization of leukemia samples. Despite growing interest in the molecular mechanisms of the development, maintenance, and therapy of leukemia, these studies either monitor a single sample per experimental animal or utilize vector libraries that do not permit the real-time tracking of cells with similar properties.37–40 Our newly developed FGB vector system employs a different strategy by providing a small number of color codes for tracking unique cell populations in multiplex flow cytometry-driven real-time assays. This allows properties of cellular populations, e.g., differentiation potential, size and dynamic expansion, or contraction processes, to become readily accessible and make the FGB platform a versatile tool for small-scale screening approaches.

The initial development of the FGB vector platform sought to allow for color coding and tracking of mixed target cell populations independent of a priori sorting steps.32 In particular, abbreviated lentiviral transduction and transplantation protocols offered enhanced gene marking and preservation of stemness for cell types that would benefit from short-term in vitro cultivation times, such as HSCs.41–43 In addition, we recognized that this tool could be adapted to yield improved readouts in multiplexing experiments with leukemic cells if initiated with controlled ratios of color-coded cells per cell mix. For this purpose, stringent sorting procedures were established that routinely yielded color-coded H9M cell purities >95%, allowed for longitudinal tracking of single color-coded populations, and showed stable in vitro and in vivo FGB vector-mediated expression of all six color codes without altering cell properties (Figures 1 and 2). The advantage of in vitro multiplexing became apparent, when single color codes occasionally outcompeted the other five populations (Figure 1F), despite stable maintenance of all color codes when monitored in isolation. Since DNA barcoding of cell lines and mesenchymal stem cells previously detected clonal restriction, color coding may represent a simple method to investigate heterogeneous growth properties in vitro, albeit requiring integration site analyses for the assessment of clonal complexities.44–46

To extend these in vitro studies on population dynamics, we employed FGB for the visualization of hematopoietic reconstitution and leukemogenesis dynamics in an in vivo H9M transplantation model (Figures 3 and S6). At 3 weeks post-transplantation, recipients of 6xFGB H9M cell mixes displayed an average of 4.4 color codes with contributions of >10% to donor-derived CD45+ PB. Color code frequencies subsequently decreased so that the majority of moribund mice only contained a single dominant color code in bulk CD45+ PB cells (Figure 3C). Nevertheless, as shown by secondary transplantation experiments, minor populations from primary BM samples were still capable of expanding in paired secondary recipients (Figure S7B). This argues against the development of dominant color codes purely by the stochastic distribution of limited color-coded LSC numbers in the graft. It rather appears more likely, that stochastic events, such as the acquisition of secondary mutations, insertional mutagenesis, epigenetic alterations, or pre-determined cell autonomous characteristics within a mixed cell population,45,47,48 may have influenced the competitive expansion of a color-coded population over time. Although the investigation of the underlying molecular aberrations exceeded the scope of this manuscript, we successfully established sorting strategies for the enrichment of color-coded LSC subpopulations (Figure S4), which may aid comparative gene expression studies and clonality assessments. In light of the previous reported clonal nature of H9M leukemia,35,48 it would, however, be challenging to dissect, if our FGB approach suggested clonal restriction because of the transplantation of limited LSC numbers or as a result of competitive clonal outgrowth.

Interestingly, the Scadden group30 recently published the “HUE” mouse model that utilizes stochastic recombination for the random
creation of >1 \times 10^3 color codes. Tracking of up to 15 color-coded HSCs in multiplex transplantation assays by flow cytometry revealed dynamic changes in the color code composition early after transplantation, before the manifestation of a stable pattern, mainly consisting of 1–3 color codes at later time points. Since these results compare to our observations in the H9M AML model, we further underline the feasibility of color coding approaches for the investigation of dynamic cell behavior in vivo. However, while the HUE mouse model provides a greater selection of color codes, due to subtle differences in fluorescent properties, not all of them might be suitable for flow cytometry-driven cell tracking. In contrast, the lentiviral FGB approach clearly benefits from the generation of a priori defined color codes in a variety of cell types without the requirement for transgenic animals.

Studies involving in vitro drug treatment of leukemic cells typically focus on the assessment of bulk cell survival, due to a lack of markers allowing for the prospective isolation of pure LSC population. FGB screens, therefore, require in vivo assessment of drug efficacy. FGB thus presents a potent tool to efficiently facilitate these assays through the ability to subject in vitro drug-exposed cells to monitoring in a single animal or culture well. The importance of this in vivo verification step became apparent when in vitro treatment of H9M cells with the HDAC-inhibitor Entinostat only impaired competitive in vitro cell growth at concentrations >1 \mu M (Figures 5B and 5C), but led to a 50% reduced homing rate at 463.8 nM ± 141.3 in short-term in vivo assays (Figures 5G–5I). Importantly, these data are comparable to results from the Thompson group, who exposed primary H9M leukemia cells to 300 nM Entinostat and reported a reduction in H9M leukemogenicity and extended survival of recipient mice. This suggests that the multiplex FGB screening platform may be especially applicable to drug screening approaches in the context of leukemia research and potentially in regenerative medicine. In addition to detecting qualitative differences; e.g., resistance to drug treatment, adaptation of competitive transplantation assays also facilitated quantification of the competitive fitness of cells, when initiated with different cell concentrations per color code. Therefore, MLDA experiments allowed for estimation of LIC frequencies in a limited number of mice (Figure 4), and similar studies may be feasible for assessing drug-dependent changes in LIC numbers.

Given that the current FGB platform in comparison to conventional transplantation assays permits a 6- to 12-fold reduction in mouse numbers, FGB promises accelerated data acquisition, as well as increased reproducibility of results from transplantation studies. However, the potential of the FGB vector platform extends further, as evidenced by our recently reported applications for marking and tracking of HSC, CRISPR/Cas9-mediated genome modifications, DNA barcoding, and miRNA screening. With the anticipated continuing expansion in the repertoire of fluorescent marker proteins, as well as in the power of flow cytometers to separate fluorophores with similar emission spectra, the complexity of the FGB platform will also continue to expand making FGB amenable to even more ambitious multiplexing experiments.

**MATERIALS AND METHODS**

**Cell Culture**

293T cells for the production of lentiviral particles were maintained in DMEM with 4,500 mg/L glucose (STEMCELL Technologies) supplemented with 10% Performance Plus fetal calf serum (PP-FCS), 100 U/mL penicillin + 100 \mu g/mL streptomycin (Pen/Strep), and 0.1 mg/mL sodium pyruvate (all Gibco; DMEM+*). H9M cells were maintained in 36SF medium consisting of DMEM supplemented with 15% FCS (STEMCELL Technologies, product #06250), Pen/Strep, glutamine and 100 ng/mL murine stem cell factor (mSCF; R&D Systems), 10 ng/mL human interleukin-6 (hIL-6), and 6 ng/mL murine IL-3 (mIL-3) (both STEMCELL Technologies).

**Generation of Hoxa9 and Meis1 Overexpressing BM Cell Lines**

H9M overexpressing BM cells were generated as previously described. In brief, C57BL/6:Pep3b (Pep3b; CD45.1*) and C57BL/6 (CD45.2*) mice were injected with 150 mg/kg 5-fluorouracil. BM cells were harvested 4 days later and were then pre-stimulated for 2 days in 36SF medium. Cells were subsequently seeded onto irradiated (40 Gy) GP+E–86 MSCV–Meis1–ires–Hoxa9–pgk–neo retroviral producer cells. At 2 days later, transduced cells were subjected to in vitro selection with 750 \mu g/mL G418 for 7–14 days depending on non-transduced control cells survival. Selected cells were subsequently expanded and frozen for later use. In total, four independent H9M lines (CD45.1Rep1, CD45.1Rep2, CD45.2Rep1, and CD45.2Rep2) were generated through independent transduction and selection processes.

**Viral Vectors, Virus Production, and Gene Transfer**

The lentiviral 6xFGB platform was described previously. In brief, a silencing resistant spleen focus forming virus promoter-derivative (CSF) drives the expression of either one of six fluorescent color codes. Color codes consist of GFP, YFP, or mKO2 derivatives described. The production of concentrated FGB lentiviral supernatants was performed as previously described. For transduction, 1 \times 10^5 H9M cells were seeded in 100 \mu L 36SF medium supplemented with 4 \mu g/mL protamine sulfate into 96-well round bottom plates before the addition of a single concentrated FGB vector supernatant per well. Cells were washed after overnight transduction, and samples with comparable gene transfer rates (typically between 40%–80%) were subsequently expanded for purification of color-coded populations by fluorescent-activated cell sorting (FACS). The sorting purity was checked before the initiation of tracking experiments, and the day of the first flow cytometric analysis with subsequent sample mixing was considered d0.

**Entinostat Treatment for Dose-Response Assessment and Transplantation**

Entinostat (Selleckchem) was dissolved in DMSO and added to 1 \times 10^5 H9M cells seeded into 96-well plates (flat bottom) in 100 \mu L
BM cells from short-term homing assays were stained with FlowJo (Tristar) and tracked over time. All data were recorded on an LSRFortessa dead cell exclusion. 12xFGB H9M cell mixes were stained likewise and experimental protocols were approved by the University of British Columbia Animal Care Committee. For short-term assays, cell mixes were prepared with 5 × 10^5 cells for each of the six CD45.1-derived color-coded populations and each of the six CD45.2-derived color-coded populations. Cell mixes were subsequently injected into lethally irradiated CD45.1 × CD45.2 F1 mice, and mice were sacrificed 24 hr after injection. All mice were monitored daily, and experimental protocols were approved by the University of British Columbia Animal Care Committee.

**Flow Cytometry**

H9M suspension cells were pelleted and resuspended in PBS (Gibco) supplemented with 2% FBS and 1 μM 4′,6-diamidino-2-phenylindole (DAPI; Sigma Aldrich) before flow cytometric analysis. Aliquots of BM cells from moribund mice were stained with CD11b-APC/Cy7 (M1/70), Gr1-Alexa Fluor 700 (RB6-8C5), cKit-PE/Cy7 (2B8), B220-biotin (RA3-6B2), CD3e-biotin (145-2C11), and optionally CD45.1-APC (A20) or CD45.2-APC (104) (all BioLegend), prior to staining with Streptavidin-eFluor450 (eBioscience). Data acquisition was performed in the presence of 0.5 μg/mL propidium iodide (PI). PB nucleated cells were stained with CD45-APC/Cy7, Gr1-Alexa Fluor 700, cKit-PE/Cy7, and either CD45.1-APC or CD45.2-APC antibodies. Cells were resuspended in 1 μM DAPI for flow cytometric analysis. BM cells from short-term homing assays were flushed from the tibia, femurs, and iliac crests of recipient mice before staining with CD45.1-Pacific Blue (A20; BioLegend) and CD45.2-APC and 0.5 μg/mL PI for dead cell exclusion. 12xFGB H9M cell mixes were stained likewise and tracked over time. All data were recorded on an LSRFortessa flow cytometer (BD Biosciences), and data analyses were performed with FlowJo (Tristar).

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes nine figures and can be found with this article online at http://dx.doi.org/10.1016/j.omtm.2017.05.007.
models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32, 941–946.

11. Imren, S., Heuser, M., Gasparetto, M., Beer, P.A., Norddahl, G.L., Xiang, P., Chen, L., Berg, T., Ryhsan, G.W., Rosten, P., et al. (2014). Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXDX13. Blood 126, 3608–3612.

12. Pabst, C., Kroel, I., Fares, I., Boucher, G., Mariner, A., Lemieux, S., Hébert, J., and Sauvageau, G. (2014). Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat. Methods 11, 436–442.

13. Wei, J., Wunderlich, M., Fox, C., Alvarez, S., Cigadoasa, J.C., Jenkins, J.R., Zheng, Y., Cancelas, J.A., Gu, Y., Jansen, M., et al. (2008). Microenvironment determines lineage fate in a human model of MLL AP-1 leukemia. Cancer Cell 13, 483–495.

14. Buechele, C., Breese, E.H., Schenck, D., Lin, C.H., Jeong, I., Duque-Afonso, J., Wong, S.H., Smith, K.S., Negrin, R.S., Porteus, M., and Cleary, M.L. (2015). MLL leukemia induction by genome editing of human CD34+ hematopoietic cells. Blood 126, 1683–1694.

15. Ellegast, J.M., Rauch, P.J., Kottovnyuk, L.V., Müller, R., Wagner, U., Saito, Y., Wildner-Verhey van Wijk, N., Fritz, C., Rafei, A., Lysenko, V., et al. (2016). inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. Blood 128, 2130–2134.

16. Wunderlich, M., Chow, F.S., Link, K.A., Mizukawa, B., Perry, R.L., Carroll, M., and Lu, R., Neff, N.F., Quake, S.R., and Weissman, I.L. (2011). Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral fluorescent proteins using confocal and multiphoton microscopy. Blood 120, e105–e116.

17. McDermott, S.P., Eppert, K., Notta, F., Isaac, M., Datti, A., Al-Awar, R., Wrana, J., Abkowitz, J.L., Persik, M.T., Shelton, G.H., Ott, R.L., Kiklevich, J.V., Catlin, S.N., and Malide, D., Métais, J.Y., and Dunbar, C.E. (2012). Dynamic clonal analysis of murine hematopoietic stem and progenitor cells marked by 5 fluorescent proteins using confocal and multiphoton microscopy. Blood 120, e105–e116.
47. Jung, N., Dai, B., Gentles, A.J., Majeti, R., and Feinberg, A.P. (2015). An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat. Commun. 6, 8489.

48. Jin, G., Yamazaki, Y., Takuwa, M., Takahara, T., Kaneko, K., Kuwata, T., Miyata, S., and Nakamura, T. (2007). Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109, 3998–4005.

49. Mulgrew, N.M., Kettle, L.M., Ramsey, J.M., Cull, S., Smyth, L.J., Mervyn, D.M., Bijl, J.J., and Thompson, A. (2014). c-Met inhibition in a HOXA9/Meis1 model of CN-AML. Dev. Dyn. 243, 172–181.

50. Fares, I., Chagraoui, J., Gareau, Y., Gingras, S., Ruel, R., Mayotte, N., Gazar, E., Knapp, D.J., Miller, P., Ngom, M., et al. (2014). Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 345, 1509–1512.

51. Boitano, A.E., Wang, J., Romeo, R., Bouchez, L.C., Parker, A.E., Sutton, S.E., Walker, J.R., Flaveny, C.A., Perdew, G.H., Denison, M.S., et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345–1348.

52. Thorsteinsdottir, U., Mamo, A., Kroon, E., Jerome, L., Bijl, J., Lawrence, H.J., Humphries, K., and Sauvageau, G. (2002). Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 99, 121–129.

53. Maetzig, T., Brugman, M.H., Bartels, S., Heinz, N., Kustikova, O.S., Modlich, U., Li, Z., Galla, M., Schiedlmayer, B., Schambach, A., and Baum, C. (2011). Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood 117, 3053–3064.